Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Faulty hip implants...

    Faulty hip implants Johnson and Johnson directed to pay Rs 25 Lakh to 67 patients who had revision surgery

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-05-31T15:34:18+05:30  |  Updated On 31 May 2019 3:34 PM IST
    Faulty hip implants Johnson and Johnson directed to pay Rs 25 Lakh to 67 patients who had revision surgery
    The Central Drugs Standard Control Organisation (CDSCO) had earlier asked the company Johnson and Johnson to pay Rs 65 lakh, Rs 74 lakh, Rs 1 crore and Rs 90.26 lakh respectively to four patients.

    New Delhi: The Delhi High Court Thursday directed Johnson and Johnson to make an interim payment of Rs 25 lakh each to 67 patients who have undergone revision surgeries for alleged faulty hip implants made by the company.


    The court's direction came after the company said it has verified that these patients have undergone revision surgery and it was voluntarily paying them Rs 25 lakh as compensation.

    Justice Vibhu Bakhru asked the company to disburse the cheques to the claimants within two weeks and listed the matter for further hearing in August 8.

    The company, through senior advocate Amit Sibal, clarified that the payment should not be considered as an admission of liability or a precedent.

    Read Also: Compensation formula: Delhi HC junks Johnson and Johnson’s plea


    The court made clear that it has not examined the controversy involved and this payment will not prejudice the rights of patients from seeking any further sum of compensation from the company.


    It also said that in case any other judicial forum awards a compensation higher than Rs 25 lakh to the patients, the company would pay the balance amount only.

    The court further said that in case the affected patients do not succeed in their claims before any other forum, the company would not be entitled for any refund of its voluntary payment of Rs 25 lakh.

    In a statement, a company spokesperson said, "We are very pleased to make compensation payments as Johnson & Johnson Private Limited volunteered to do.

    Read Also: Now Supreme Court seeks response Johnson and Johnson on faulty Implant


    The spokesperson, however, said, "We continue to believe the formula for compensation needs to be within a fully transparent and legal framework arrived at through due process."


    The company is committed to providing assistance, including appropriate compensation under the law, to ASR patients in India who have undergone revision surgery, the spokesperson added.

    The Central Drugs Standard Control Organisation (CDSCO) had earlier asked the company to pay Rs 65 lakh, Rs 74 lakh, Rs 1 crore and Rs 90.26 lakh respectively to four patients.

    As an interim, the court had asked the company pay Rs 25 lakh to these four patients for whom CDSCO has already issued orders, after verification of their documents.

    The court was hearing the company's plea challenging a press release issued by the Ministry of Health and Family Welfare asking it to pay compensation to all the affected patients, as determined by the reports of the committees formed to examine the issues relating to its faulty hip implants.

    The company also challenged the orders by which it was directed to pay compensation to patients.

    It contended that the Centre has no jurisdiction under the Drugs and Cosmetics Act to fix and enforce the compensation.

    Read Also: Johnson and Johnson, Health Ministry to meet to Discuss compensation to faulty implant victims


    It said the Centre's orders fixing the compensation was based on a formula and reports by a set of expert committees and recommendations which have already been challenged by the company and are pending in the high court.


    It maintained that the Drugs and Cosmetics Act does not have any provisions that provide for a formula for payment of compensation in the matters pertaining to medical devices.

    In the earlier petition filed in December last year, the company sought quashing of a government's press release informing the general public about the formula worked out by an expert committee to compensate patients who received the faulty hip implants produced by the pharma major's subsidiary, DePuy Orthopaedics Inc (USA).

    It has also challenged the report of the expert committee -- headed by R K Arya, Director, Sports Injury Centre -- which worked out the compensation formula.

    Besides, it has sought quashing of the report of another committee -- headed by Arun Agarwal, Professor of ENT, Maulana Azad Medical College -- which was appointed by the Health Ministry for looking into the allegations of faulty hip replacement implants.

    According to the Arya committee report, the compensation payable to patients would be determined in terms of the disability by the faulty hip implants in relation to their age.

    The pharma major had earlier told the court that as a result of the press release, people are "landing at its doorstep" for compensation and contended that the government's public announcement was made without any legal basis.

    Public interest litigation (PIL), which was earlier before the Supreme Court, has alleged that "faulty" and "deadly" hip implants have been fitted into the bodies of 4,525 Indian patients.

    The plea has contended that DePuy makes, sells and exports medical implants, including articular surface replacements (ASR) hip implants which have been withdrawn by the firms on their own in 2010 on the ground that they were defective.

    According to the PIL, the firms "illegally sold DePuy ASR Hip Implants in India from 2005 to 2006".
    articular surface replacementsASRASR hip implantsCDSCOCentral Drugs Standard Control OrganisationcompensationDelhi high courtDrugs and Cosmetics ActHChip implantsIndiainterim paymentJ&JJohnson and Johnsonjohnson and johnson hip implant caseMinistry of Health and Family WelfarePILPublic Interest LitigationSupreme Courtsurgery
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok